BioSpace News Archive

Drug Development

Sarepta Expands Gene Therapy Pipeline in $30 Million Equity Deal with Lacerta

Cambridge, Mass.-based Sarepta Therapeutics expanded its gene therapy pipeline up to 11 in an equity deal with Lacerta Therapeutics. Investing $30 million into Alachua, Florida-based Lacerta Therapeutics, Sarepta gained access to the company’s AAV-based CNS-targeted gene therapies.

August 9, 2018
·
2 min read
·
Mark Terry
Policy

A Deep Dive into Teva Pharma Financials Shows Significant Weakness and Optimism

Last week, Teva Pharmaceutical released what tried to be an optimistic second-quarter financial report, despite revenues that had decreased by 18 percent and softening sales of its biggest product, Copaxone.

August 9, 2018
·
3 min read
·
Mark Terry
FDA

GW Pharmaceuticals Slaps Price Tag on Cannabis-Based Epilepsy Drug

GW Pharmaceuticals has finally revealed the price of its cannabis-based epilepsy drug Epidiolex.

August 9, 2018
·
3 min read
·
Alex Keown
FDA

FDA Approves New Generic Drug Under Novel Pathway Aimed at Increasing Competition

The U.S. Food and Drug Administration approved a new generic potassium chloride oral solution under a novel term called the Competitive Generic Therapy designation.

August 9, 2018
·
2 min read
·
Alex Keown
BioForest

Researchers Debate on Whether CRISPR Works in Embryos

CRISPR, the gene editing technique that promises designer babies, to end to all disease as we know it, and biohacking where individuals could change their own genome to include that of fluorescent jellyfish or lobster claws, seems to have more problems than originally thought.

August 9, 2018
·
4 min read
·
Mark Terry
BioMidwest

August 10 Research Roundup: Type 2 Diabetes, Breast Cancer, Ebola and Koalas

There are plenty of great scientific research stories out this week. Here’s a look at just a few of them.

August 9, 2018
·
8 min read
·
Mark Terry
Drug Development

FDA Advisory Panel Supports Paratek’s Investigational Antibiotic, PDUFA Set for October

Shares of Paratek Pharmaceuticals are climbing in pre-market trading after the company announced a U.S. Food and Drug Administration advisory committee voted overwhelmingly in favor of the company’s intravenous and oral treatments for acute bacterial skin and skin structure infections (ABSSSI).

August 9, 2018
·
2 min read
·
Alex Keown
Drug Development

Ampio Pharma Shares Plunge 71% After Bad News from FDA

The U.S. Food and Drug Administration (FDA) rejected Englewood, Colorado-based Ampio Pharmaceuticals’ Biologics License Application (BLA) for its drug for osteoarthritis of the knee, Ampion.

August 9, 2018
·
2 min read
·
Mark Terry
Deals

Beleaguered OvaScience is Absorbed in Reverse Merger by Michigan-based Millendo Therapeutics

Shares of struggling OvaScience have dipped 8 percent this morning after the company announced it entered into an all-stock reverse merger agreement with privately-held Millendo Therapeutics, Inc. of Ann Arbor, Mich.

August 9, 2018
·
2 min read
·
Alex Keown
Drug Development

Emergent BioSolutions Buys PaxVax for $270 Million

Emergent BioSolutions, headquartered in Gaithersburg, Maryland, inked a deal to buy PaxVax, based in Redwood City, California, for $270 million in cash.

August 9, 2018
·
2 min read
·
Mark Terry